Listing of Color Additives Exempt From Certification; Reactive Blue 246 and Reactive Blue 247 Copolymers, 19413-19415 [2013-07294]
Download as PDF
pmangrum on DSK3VPTVN1PROD with RULES
Federal Register / Vol. 78, No. 62 / Monday, April 1, 2013 / Rules and Regulations
its Web site the amount of annual
charges to be flowed through per unit of
energy sold or transported (ACA unit
charge) for that fiscal year. A company’s
ACA clause must be filed with the
Commission and must incorporate by
reference the ACA unit charge for the
upcoming fiscal year as posted on the
Commission’s Web site. A company
must incorporate by reference the ACA
unit charge posted on the Commission’s
Web site in each of its rate schedules
applicable to sales or transportation
deliveries. The company must apply the
ACA unit charge posted on the
Commission’s Web site to the usage
component of rate schedules with twopart rates. A company may recover
annual charges through an ACA unit
charge only if its rates do not otherwise
reflect the costs of annual charges
assessed by the Commission under
§ 382.106(a) of this chapter. The
applicable annual charge, required by
§ 382.103 of this chapter, must be paid
before the company applies the ACA
unit charge. Upon payment to the
Commission of its annual charges, the
ACA unit charge for that fiscal year will
be incorporated by reference into the
company’s tariff, effective throughout
that fiscal year.
(b) Application for rate treatment
authorization. A company seeking
authorization to use an ACA unit charge
must file with the Commission a
separate ACA tariff record containing:
(1) A statement that the company is
collecting an ACA unit charge, as
calculated by the Commission,
applicable to all the pipeline’s sales and
transportation rate schedules,
(2) A statement that the ACA unit
charge, as revised annually and posted
on the Commission’s Web site, is
incorporated by reference into the
company’s tariff,
(3) For companies with existing ACA
clauses, a proposed effective date of the
tariff change of October 1 of the fiscal
year; for companies seeking to utilize an
ACA clause after October 1 of the fiscal
year, a proposed effective date 30 days
after the filing of the tariff record, unless
a shorter period is specifically requested
in a waiver petition and approved), and
(4) A statement that the pipeline will
not recover any annual charges recorded
in FERC Account 928 in a proceeding
under subpart D of this part.
*
*
*
*
*
[FR Doc. 2013–07078 Filed 3–29–13; 8:45 am]
BILLING CODE 6717–01–P
VerDate Mar<15>2010
13:26 Mar 29, 2013
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 73
[Docket Nos. FDA–2011–C–0344 and FDA–
2011–C–0463]
Listing of Color Additives Exempt
From Certification; Reactive Blue 246
and Reactive Blue 247 Copolymers
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
SUMMARY: The Food and Drug
Administration (FDA or we) is
amending the color additive regulations
to provide for the safe use of additional
copolymers of 1,4-bis[4-(2methacryloxyethyl)phenylamino]
anthraquinone (C.I. Reactive Blue 246)
and copolymers of 1,4-bis[(2hydroxyethyl)amino]-9,10anthracenedione bis(2-methyl-2propenoic)ester (C.I. Reactive Blue 247)
as color additives in contact lenses. This
action is in response to two color
additive petitions (CAPs) filed by
CooperVision, Inc.
DATES: This rule is effective May 2,
2013. See section VII for related
information on the filing of objections.
Submit either electronic or written
objections and requests for a hearing by
May 1, 2013.
ADDRESSES: You may submit either
electronic or written objections and
requests for a hearing, identified by
Docket No. FDA–2011–C–0344 (C.I.
Reactive Blue 246) or FDA–2011–C–
0463 (C.I. Reactive Blue 247), by any of
the following methods:
Electronic Submissions
Submit electronic objections in the
following ways:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Written Submissions
Submit written objections in the
following ways:
• Mail/Hand delivery/Courier (for
paper or CD–ROM submissions):
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
Instructions: All submissions received
must include the Agency name and the
appropriate docket number (FDA–2011–
C–0344 for C.I. Reactive Blue 246 or
FDA–2011–C–0463 for C.I. Reactive
Blue 247) for this rulemaking. All
objections received will be posted
PO 00000
Frm 00021
Fmt 4700
Sfmt 4700
19413
without change to https://
www.regulations.gov, including any
personal information provided. For
detailed instructions on submitting
objections, see the ‘‘Objections’’ heading
of the SUPPLEMENTARY INFORMATION
section.
Docket: For access to the dockets to
read background documents or
objections received, go to https://
www.regulations.gov and insert the
docket numbers, found in brackets in
the heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Regarding CAP 1C0291 (C.I. Reactive
Blue 246): Judith Kidwell, Center for
Food Safety and Applied Nutrition
(HFS–265), Food and Drug
Administration, 5100 Paint Branch
Pkwy., College Park, MD 20740–3835,
240–402–1071.
Regarding CAP 1C0292 (C.I. Reactive
Blue 247): Teresa Croce, Center for Food
Safety and Applied Nutrition (HFS–
265), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park,
MD 20740–3835, 240–402–1281.
SUPPLEMENTARY INFORMATION:
I. Introduction
In a notice published in the Federal
Register of June 28, 2011 (76 FR 37690),
we announced that CooperVision, Inc.,
6150 Stoneridge Mall Rd., suite 370,
Pleasanton, CA 94588 (petitioner) had
filed two color additive petitions (CAP
1C0291 and CAP 1C0292). The petitions
proposed to amend the color additive
regulations in 21 CFR part 73, subpart
D, Medical Devices, to provide for the
safe use of additional copolymers of 1,4bis[(2-hydroxyethyl)amino]-9,10anthracenedione bis(2-methyl-2propenoic)ester (C.I. Reactive Blue 247)
and additional copolymers of 1,4-bis[4(2-methacryloxyethyl)phenylamino]
anthraquinone (C.I. Reactive Blue 246)
as color additives in contact lenses. The
color additives are produced by
copolymerizing the reactive dyes with
various vinyl and/or acrylic monomers
such that the dyes are bound covalently
and cross-linked in the resulting
polymer matrix.1
1 According to the International Union of Pure
and Applied Chemistry (IUPAC), a vinyl polymer
is prepared from a monomer containing the vinyl
group –CH=CH2. Acrylic polymers are one subclass
of vinyl polymers; however, not all acrylic
polymers (e.g., methacrylic polymers) are vinyl
polymers using the IUPAC definition (Ref. 1). The
term ‘‘vinyl and/or acrylic monomers’’ includes
monomers that form vinyl polymers, monomers that
form acrylic polymers (e.g., acrylate, methacylate,
acrylamide, etc.), or any combination thereof.
E:\FR\FM\01APR1.SGM
01APR1
19414
Federal Register / Vol. 78, No. 62 / Monday, April 1, 2013 / Rules and Regulations
Current regulations for C.I. Reactive
Blue 246 and C.I. Reactive Blue 247
copolymers (21 CFR 73.3106 and
73.3100, respectively) list the reaction
products of these reactive dyes with
specific vinyl and/or acrylic monomers
for use in coloring contact lenses.2 The
petitions sought to expand the list of
permitted monomers to include any
suitable vinyl and/or acrylic monomer
capable of forming a contact lens. The
petitions were filed under section 721 of
the Federal Food, Drug, and Cosmetic
Act (the FD&C Act) (21 U.S.C. 379e). In
§ 73.3100, Reactive Blue 247 is
identified as 1,4-bis[(2-hydroxyethyl)
amino]-9,10-anthracenedione bis(2propenoic)ester. As part of this final
rule, we are correcting the nomenclature
for Reactive Blue 247 by inserting ‘‘2methyl’’ before ‘‘2-propenoic.’’
II. Safety Evaluation
pmangrum on DSK3VPTVN1PROD with RULES
Under section 721(b)(4) of the FD&C
Act, a color additive may not be listed
for a particular use unless the data
available to FDA establishes that the
color additive is safe for that use. Our
color additive regulations at 21 CFR
70.3(i) define safe to mean that there is
‘‘convincing evidence that establishes
with reasonable certainty that no harm
will result from the intended use of the
color additive.’’
As part of our safety evaluation of the
color additives, we considered exposure
to unreacted C.I. Reactive Blue 246 and
247 and any impurities (e.g., reaction
byproducts) from the petitioned use of
the color additives. We also considered
results from skin sensitization, ocular
irritation, and cytotoxicity studies with
either representative lens materials or
extracts from the lens materials (i.e., the
color additives that are the subjects of
the petitions).3
2 21 CFR 73.3106 originally allowed for the safe
use of 1,4-bis[4-(2-methacryloxyethyl)
phenylamino]anthraquinone (C.I. Reactive Blue
246) copolymerized with hydroxyethyl
methacrylate monomer or a blend of hydroxyethyl
methacrylate and N-vinyl pyrrolidone monomers
(58 FR 17506, April 5, 1993). The regulation was
later amended to also allow for the safe use of C.I.
Reactive Blue 246 copolymerized with a blend of
3-[tris(trimethylsiloxy)silyl]propyl vinyl carbamate
and N-vinyl pyrrolidone monomers (60 FR 10495,
February 27, 1995).
21 CFR 73.3100 allows for the safe use of 1,4-bis[
(2-hydroxyethyl)amino]-9,10-anthracenedione
bis(2-propenoic)ester (C.I. Reactive Blue 247)
copolymerized either with glyceryl methacrylate,
methyl methacrylate, and ethylene glycol
dimethacrylate monomers, or with N,N-dimethyl
acrylamide, methyl methacrylate, and ethylene
glycol dimethacrylate monomers (61 FR 51584,
October 3, 1996).
3 Both the petitioner’s representative formulations
and currently regulated formulations consist of
either C.I. Reactive Blue 246 or C.I. Reactive Blue
247 copolymerized with various vinyl and/or
acrylic monomers.
VerDate Mar<15>2010
13:26 Mar 29, 2013
Jkt 229001
A. C.I. Reactive Blue 246
We calculated an exposure estimate
for C.I. Reactive Blue 246 from its
proposed use in three representative
contact lens formulations using vinyl
and/or acrylic monomers based on
results from a leachability study that
was conducted by the petitioner. This
study demonstrated that there was no
detectable migration of C.I. Reactive
Blue 246 at the limit of detection (LOD)
of an appropriate analytical method for
any of the lens formulations evaluated.
We estimated the potential exposure to
any one impurity using the maximum
amount of total impurities determined
in C.I. Reactive Blue 246.
The average daily exposure to C.I.
Reactive Blue 246 from its proposed use
would be no greater than 13 nanograms
(ng)/person/day (p/d) and the maximum
exposure to any one impurity will not
exceed 0.6 ng/p/d. These estimates
represent worst-case exposure, and the
actual exposure to C.I. Reactive Blue
246 and its impurities from the use of
the color additive in contact lenses is
expected to be significantly lower.
Based on data submitted in the
petitions, as well as other relevant
information, we note that it is highly
unlikely that either C.I. Reactive Blue
246 or its components would migrate
from the contact lens into the aqueous
environment of the eye because the
reactive dye is covalently bound and
cross-linked during polymerization such
that any migration from the resulting
copolymer matrix as a result of the
proposed uses will be negligible.
Therefore, we conclude that the
exposure to the color additive,
including any impurities that may be
present in it, from the petitioned use
would be negligible (Ref. 2).
The petitioner submitted data from 24
toxicology studies on either
representative lens materials or extracts
from representative lens materials with
and without C.I. Reactive Blue 246 to
establish the safety of the
copolymerized color additives of C.I.
Reactive Blue 246. Studies included
guinea pig maximization studies, in vivo
ocular irritation studies in rabbits, and
cytotoxicity studies. Based on our
review of these studies, we conclude
that there is no evidence of toxicity (Ref.
3).
B. C.I. Reactive Blue 247
We calculated an exposure estimate
for C.I. Reactive Blue 247 from its
proposed use in three representative
contact lens formulations using vinyl
and/or acrylic monomers based on
results from a leachability study that
was conducted by the petitioner. This
PO 00000
Frm 00022
Fmt 4700
Sfmt 4700
study demonstrated that there was no
detectable migration of C.I. Reactive
Blue 247 at the LOD of an appropriate
analytical method for any of the lens
formulations evaluated. We estimated
the potential exposure to any one
impurity using the maximum amount of
total impurities determined in C.I.
Reactive Blue 247.
The average daily exposure to C.I.
Reactive Blue 247 from its proposed use
would be no greater than 10 ng/p/d and
the maximum exposure to any one
impurity will not exceed 0.5 ng/p/d.
These estimates represent worst-case
exposure, and the actual exposure to C.I.
Reactive Blue 247 and its impurities
from the use of the color additive in
contact lenses is expected to be
significantly lower. Based on data
submitted in the petitions, as well as
other relevant information, we note that
it is highly unlikely that either C.I.
Reactive Blue 247 or its components
would migrate from the contact lens
into the aqueous environment of the eye
because the reactive dye is covalently
bound and cross-linked during
polymerization such that any migration
from the resulting copolymer matrix as
a result of the proposed uses will be
negligible. Therefore, we conclude that
the exposure to the color additive,
including any impurities that may be
present in it, from the petitioned use
would be negligible (Ref. 4).
The petitioner submitted data from 24
toxicology studies on either
representative lens materials or extracts
from representative lens materials with
and without C.I. Reactive Blue 247 to
establish the safety of the
copolymerized color additives of C. I.
Reactive Blue 247. Studies included
guinea pig maximization studies, in vivo
ocular irritation studies in rabbits, and
cytotoxicity studies. Based on our
review of these studies, we conclude
that there is no evidence of toxicity (Ref.
5).
III. Conclusion
Based on the data contained in the
two petitions and other available
relevant material, we conclude that the
petitioned use of the reaction products
formed by copolymerizing either C.I.
Reactive Blue 246 or C.I. Reactive Blue
247 with vinyl and/or acrylic-monomers
to form colored contact lenses is safe
and that the color additives will achieve
their intended technical effect. We
further conclude that there is no need
for imposing a limitation on the amount
of color additive to be used, beyond the
limitation that reactants may be used in
amounts not to exceed the minimum
reasonably required to accomplish the
intended technical effect. Therefore, we
E:\FR\FM\01APR1.SGM
01APR1
Federal Register / Vol. 78, No. 62 / Monday, April 1, 2013 / Rules and Regulations
are amending the regulations in part 73
(21 CFR part 73) as set forth in this
document. In addition, based upon the
factors listed in § 71.20(b) (21 CFR
71.20(b)), we have determined that
batch certification of these color
additives is not necessary for the
protection of the public health.
IV. Public Availability of Documents
In accordance with § 71.15 (21 CFR
71.15), the petition and the documents
that we considered and relied upon in
reaching our decision to approve the
petition will be made available for
public disclosure (see FOR FURTHER
INFORMATION CONTACT). As provided in
§ 71.15, we will delete from the
documents any materials that are not
available for public disclosure.
V. Environmental Impact
We previously considered the
environmental effect of this rule, as
stated in the June 28, 2011, Federal
Register notice of petitions for CAP
1C0291 and CAP 1C0292 (76 FR 37690).
We stated that we had determined,
under 21 CFR 25.32(l), that this action
‘‘is of a type that does not individually
or cumulatively have a significant effect
on the human environment’’ such that
neither an environmental assessment
nor an environmental impact statement
is required. We have not received any
new information or comments that
would affect our previous
determination.
pmangrum on DSK3VPTVN1PROD with RULES
VI. Paperwork Reduction Act of 1995
This final rule contains no collection
of information. Therefore, clearance by
the Office of Management and Budget
under the Paperwork Reduction Act of
1995 is not required.
VII. Objections
This rule is effective as shown in the
DATES section; except as to any
provisions that may be stayed by the
filing of proper objections. Any person
who will be adversely affected by this
regulation may file with the Division of
Dockets Management (see ADDRESSES)
either electronic or written objections
regarding this document. Each objection
shall be separately numbered, and each
numbered objection shall specify with
particularity the provisions of the
regulation to which objection is made
and the grounds for the objection. Each
numbered objection on which a hearing
is requested shall specifically so state.
Failure to request a hearing for any
particular objection shall constitute a
waiver of the right to a hearing on that
objection. Each numbered objection for
which a hearing is requested shall
include a detailed description and
VerDate Mar<15>2010
17:43 Mar 29, 2013
Jkt 229001
19415
analysis of the specific factual
information intended to be presented in
support of the objection in the event
that a hearing is held. Failure to include
such a description and analysis for any
particular objection shall constitute a
waiver of the right to a hearing on the
objection. It is only necessary to send
one set of documents. Identify
documents with the appropriate docket
number found in brackets in the
heading of this document. Any
objections received in response to the
regulation may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
FDA will publish notice of the
objections that we have received or lack
thereof in the Federal Register.
Authority: 21 U.S.C. 321, 341, 342, 343,
348, 351, 352, 355, 361, 362, 371, 379e.
VIII. References
■
The following references have been
placed on display in the Division of
Dockets Management (see ADDRESSES)
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday, and are available
electronically at https://
www.regulations.gov.
´
1. Baron, M., K.-H. Hellwich, M. Hess, K.
Horie, et al, ‘‘Glossary of Class Names of
Polymers Based on Chemical Structure and
Molecular Architecture (IUPAC
Recommendations 2009)’’, Pure and Applied
Chemistry, 81(6), pp. 1131–1186, 2009.
2. Memorandum from H. Lee, Division of
Petition Review, Chemistry Review Team, to
J. Kidwell, Division of Petition Review,
Regulatory Group I, FDA, July 26, 2011.
3. Memorandum from S. Park, Division of
Petition Review, Toxicology Review Team, to
M.Harry, Division of Petition Review,
Regulatory Group I, FDA, November 30,
2011.
4. Memorandum from H. Lee, Division of
Petition Review, Chemistry Review Team, to
T.Croce, Division of Petition Review,
Regulatory Group II, FDA, August 16, 2011.
5. Memorandum from T.Walker, Division
of Petition Review, Toxicology Review Team,
to T.Croce, Division of Petition Review, FDA,
January 13, 2012.
List of Subjects in 21 CFR Part 73
Color additives, Cosmetics, Drugs,
Medical devices.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, and redelegated to
the Director, Center for Food Safety and
Applied Nutrition, 21 CFR part 73 is
amended as follows:
PART 73—LISTING OF COLOR
ADDITIVES EXEMPT FROM
CERTIFICATION
1. The authority citation for part 73
continues to read as follows:
■
PO 00000
Frm 00023
Fmt 4700
Sfmt 4700
2. Amend § 73.3100 by revising the
section heading and paragraph (a) to
read as follows:
■
§ 73.3100 1,4-Bis[(2-hydroxyethyl)amino]9,10-anthracenedione bis(2-methyl-2propenoic)ester copolymers.
(a) Identity. The color additives are
the copolymers formed as the reaction
product of 1,4-bis[(2hydroxyethyl)amino]-9,10anthracenedione bis(2-methyl-2propenoic)ester (C.I. Reactive Blue 247)
(CAS Reg. No. 109561–07–1) with one
or more vinyl and/or acrylic monomers
to form the contact lens material.
*
*
*
*
*
3. Amend § 73.3106 by revising
paragraph (a) to read as follows:
§ 73.3106 1,4-Bis[4-(2-methacryloxyethyl)
phenylamino]anthraquinone copolymers.
(a) Identity. The color additives are
the copolymers formed as the reaction
product of 1,4-bis[4(2-methacryloxyethyl)phenylamino
]anthraquinone (C.I. Reactive Blue 246)
(CAS Reg. No. 121888–69–5) with one
or more vinyl and/or acrylic monomers
to form the contact lens material.
*
*
*
*
*
Dated: March 25, 2013.
Susan M. Bernard,
Director, Office of Regulations, Policy and
Social Sciences, Center for Food Safety and
Applied Nutrition.
[FR Doc. 2013–07294 Filed 3–29–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
33 CFR Part 117
[Docket No. USCG–2013–0056]
Drawbridge Operation Regulations;
Old River, Orwood, CA
Coast Guard, DHS.
Notice of deviation from
drawbridge regulation.
AGENCY:
ACTION:
SUMMARY: The Coast Guard has issued a
temporary deviation from the operating
regulation that governs the Burlington
Northern & Santa Fe Railroad (BNSF)
Drawbridge across Old River, mile 10.4,
at Orwood, CA. The deviation is to
allow the bridge owner to perform
essential mechanical repairs on the
bridge. This deviation allows the bridge
to remain in the closed-to-navigation
position during the event.
E:\FR\FM\01APR1.SGM
01APR1
Agencies
[Federal Register Volume 78, Number 62 (Monday, April 1, 2013)]
[Rules and Regulations]
[Pages 19413-19415]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07294]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 73
[Docket Nos. FDA-2011-C-0344 and FDA-2011-C-0463]
Listing of Color Additives Exempt From Certification; Reactive
Blue 246 and Reactive Blue 247 Copolymers
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is amending the
color additive regulations to provide for the safe use of additional
copolymers of 1,4-bis[4-(2-methacryloxyethyl)phenylamino]anthraquinone
(C.I. Reactive Blue 246) and copolymers of 1,4-bis[(2-
hydroxyethyl)amino]-9,10-anthracenedione bis(2-methyl-2-propenoic)ester
(C.I. Reactive Blue 247) as color additives in contact lenses. This
action is in response to two color additive petitions (CAPs) filed by
CooperVision, Inc.
DATES: This rule is effective May 2, 2013. See section VII for related
information on the filing of objections. Submit either electronic or
written objections and requests for a hearing by May 1, 2013.
ADDRESSES: You may submit either electronic or written objections and
requests for a hearing, identified by Docket No. FDA-2011-C-0344 (C.I.
Reactive Blue 246) or FDA-2011-C-0463 (C.I. Reactive Blue 247), by any
of the following methods:
Electronic Submissions
Submit electronic objections in the following ways:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Written Submissions
Submit written objections in the following ways:
Mail/Hand delivery/Courier (for paper or CD-ROM
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
Instructions: All submissions received must include the Agency name
and the appropriate docket number (FDA-2011-C-0344 for C.I. Reactive
Blue 246 or FDA-2011-C-0463 for C.I. Reactive Blue 247) for this
rulemaking. All objections received will be posted without change to
https://www.regulations.gov, including any personal information
provided. For detailed instructions on submitting objections, see the
``Objections'' heading of the SUPPLEMENTARY INFORMATION section.
Docket: For access to the dockets to read background documents or
objections received, go to https://www.regulations.gov and insert the
docket numbers, found in brackets in the heading of this document, into
the ``Search'' box and follow the prompts and/or go to the Division of
Dockets Management, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Regarding CAP 1C0291 (C.I. Reactive
Blue 246): Judith Kidwell, Center for Food Safety and Applied Nutrition
(HFS-265), Food and Drug Administration, 5100 Paint Branch Pkwy.,
College Park, MD 20740-3835, 240-402-1071.
Regarding CAP 1C0292 (C.I. Reactive Blue 247): Teresa Croce, Center
for Food Safety and Applied Nutrition (HFS-265), Food and Drug
Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835,
240-402-1281.
SUPPLEMENTARY INFORMATION:
I. Introduction
In a notice published in the Federal Register of June 28, 2011 (76
FR 37690), we announced that CooperVision, Inc., 6150 Stoneridge Mall
Rd., suite 370, Pleasanton, CA 94588 (petitioner) had filed two color
additive petitions (CAP 1C0291 and CAP 1C0292). The petitions proposed
to amend the color additive regulations in 21 CFR part 73, subpart D,
Medical Devices, to provide for the safe use of additional copolymers
of 1,4-bis[(2-hydroxyethyl)amino]-9,10-anthracenedione bis(2-methyl-2-
propenoic)ester (C.I. Reactive Blue 247) and additional copolymers of
1,4-bis[4-(2-methacryloxyethyl)phenylamino]anthraquinone (C.I. Reactive
Blue 246) as color additives in contact lenses. The color additives are
produced by copolymerizing the reactive dyes with various vinyl and/or
acrylic monomers such that the dyes are bound covalently and cross-
linked in the resulting polymer matrix.\1\
---------------------------------------------------------------------------
\1\ According to the International Union of Pure and Applied
Chemistry (IUPAC), a vinyl polymer is prepared from a monomer
containing the vinyl group -CH=CH2. Acrylic polymers are
one subclass of vinyl polymers; however, not all acrylic polymers
(e.g., methacrylic polymers) are vinyl polymers using the IUPAC
definition (Ref. 1). The term ``vinyl and/or acrylic monomers''
includes monomers that form vinyl polymers, monomers that form
acrylic polymers (e.g., acrylate, methacylate, acrylamide, etc.), or
any combination thereof.
---------------------------------------------------------------------------
[[Page 19414]]
Current regulations for C.I. Reactive Blue 246 and C.I. Reactive
Blue 247 copolymers (21 CFR 73.3106 and 73.3100, respectively) list the
reaction products of these reactive dyes with specific vinyl and/or
acrylic monomers for use in coloring contact lenses.\2\ The petitions
sought to expand the list of permitted monomers to include any suitable
vinyl and/or acrylic monomer capable of forming a contact lens. The
petitions were filed under section 721 of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C. 379e). In Sec. 73.3100,
Reactive Blue 247 is identified as 1,4-bis[(2-hydroxyethyl)amino]-9,10-
anthracenedione bis(2-propenoic)ester. As part of this final rule, we
are correcting the nomenclature for Reactive Blue 247 by inserting ``2-
methyl'' before ``2-propenoic.''
---------------------------------------------------------------------------
\2\ 21 CFR 73.3106 originally allowed for the safe use of 1,4-
bis[4-(2-methacryloxyethyl) phenylamino]anthraquinone (C.I. Reactive
Blue 246) copolymerized with hydroxyethyl methacrylate monomer or a
blend of hydroxyethyl methacrylate and N-vinyl pyrrolidone monomers
(58 FR 17506, April 5, 1993). The regulation was later amended to
also allow for the safe use of C.I. Reactive Blue 246 copolymerized
with a blend of 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbamate
and N-vinyl pyrrolidone monomers (60 FR 10495, February 27, 1995).
21 CFR 73.3100 allows for the safe use of 1,4-bis[ (2-
hydroxyethyl)amino]-9,10-anthracenedione bis(2-propenoic)ester (C.I.
Reactive Blue 247) copolymerized either with glyceryl methacrylate,
methyl methacrylate, and ethylene glycol dimethacrylate monomers, or
with N,N-dimethyl acrylamide, methyl methacrylate, and ethylene
glycol dimethacrylate monomers (61 FR 51584, October 3, 1996).
---------------------------------------------------------------------------
II. Safety Evaluation
Under section 721(b)(4) of the FD&C Act, a color additive may not
be listed for a particular use unless the data available to FDA
establishes that the color additive is safe for that use. Our color
additive regulations at 21 CFR 70.3(i) define safe to mean that there
is ``convincing evidence that establishes with reasonable certainty
that no harm will result from the intended use of the color additive.''
As part of our safety evaluation of the color additives, we
considered exposure to unreacted C.I. Reactive Blue 246 and 247 and any
impurities (e.g., reaction byproducts) from the petitioned use of the
color additives. We also considered results from skin sensitization,
ocular irritation, and cytotoxicity studies with either representative
lens materials or extracts from the lens materials (i.e., the color
additives that are the subjects of the petitions).\3\
---------------------------------------------------------------------------
\3\ Both the petitioner's representative formulations and
currently regulated formulations consist of either C.I. Reactive
Blue 246 or C.I. Reactive Blue 247 copolymerized with various vinyl
and/or acrylic monomers.
---------------------------------------------------------------------------
A. C.I. Reactive Blue 246
We calculated an exposure estimate for C.I. Reactive Blue 246 from
its proposed use in three representative contact lens formulations
using vinyl and/or acrylic monomers based on results from a
leachability study that was conducted by the petitioner. This study
demonstrated that there was no detectable migration of C.I. Reactive
Blue 246 at the limit of detection (LOD) of an appropriate analytical
method for any of the lens formulations evaluated. We estimated the
potential exposure to any one impurity using the maximum amount of
total impurities determined in C.I. Reactive Blue 246.
The average daily exposure to C.I. Reactive Blue 246 from its
proposed use would be no greater than 13 nanograms (ng)/person/day (p/
d) and the maximum exposure to any one impurity will not exceed 0.6 ng/
p/d. These estimates represent worst-case exposure, and the actual
exposure to C.I. Reactive Blue 246 and its impurities from the use of
the color additive in contact lenses is expected to be significantly
lower. Based on data submitted in the petitions, as well as other
relevant information, we note that it is highly unlikely that either
C.I. Reactive Blue 246 or its components would migrate from the contact
lens into the aqueous environment of the eye because the reactive dye
is covalently bound and cross-linked during polymerization such that
any migration from the resulting copolymer matrix as a result of the
proposed uses will be negligible. Therefore, we conclude that the
exposure to the color additive, including any impurities that may be
present in it, from the petitioned use would be negligible (Ref. 2).
The petitioner submitted data from 24 toxicology studies on either
representative lens materials or extracts from representative lens
materials with and without C.I. Reactive Blue 246 to establish the
safety of the copolymerized color additives of C.I. Reactive Blue 246.
Studies included guinea pig maximization studies, in vivo ocular
irritation studies in rabbits, and cytotoxicity studies. Based on our
review of these studies, we conclude that there is no evidence of
toxicity (Ref. 3).
B. C.I. Reactive Blue 247
We calculated an exposure estimate for C.I. Reactive Blue 247 from
its proposed use in three representative contact lens formulations
using vinyl and/or acrylic monomers based on results from a
leachability study that was conducted by the petitioner. This study
demonstrated that there was no detectable migration of C.I. Reactive
Blue 247 at the LOD of an appropriate analytical method for any of the
lens formulations evaluated. We estimated the potential exposure to any
one impurity using the maximum amount of total impurities determined in
C.I. Reactive Blue 247.
The average daily exposure to C.I. Reactive Blue 247 from its
proposed use would be no greater than 10 ng/p/d and the maximum
exposure to any one impurity will not exceed 0.5 ng/p/d. These
estimates represent worst-case exposure, and the actual exposure to
C.I. Reactive Blue 247 and its impurities from the use of the color
additive in contact lenses is expected to be significantly lower. Based
on data submitted in the petitions, as well as other relevant
information, we note that it is highly unlikely that either C.I.
Reactive Blue 247 or its components would migrate from the contact lens
into the aqueous environment of the eye because the reactive dye is
covalently bound and cross-linked during polymerization such that any
migration from the resulting copolymer matrix as a result of the
proposed uses will be negligible. Therefore, we conclude that the
exposure to the color additive, including any impurities that may be
present in it, from the petitioned use would be negligible (Ref. 4).
The petitioner submitted data from 24 toxicology studies on either
representative lens materials or extracts from representative lens
materials with and without C.I. Reactive Blue 247 to establish the
safety of the copolymerized color additives of C. I. Reactive Blue 247.
Studies included guinea pig maximization studies, in vivo ocular
irritation studies in rabbits, and cytotoxicity studies. Based on our
review of these studies, we conclude that there is no evidence of
toxicity (Ref. 5).
III. Conclusion
Based on the data contained in the two petitions and other
available relevant material, we conclude that the petitioned use of the
reaction products formed by copolymerizing either C.I. Reactive Blue
246 or C.I. Reactive Blue 247 with vinyl and/or acrylic-monomers to
form colored contact lenses is safe and that the color additives will
achieve their intended technical effect. We further conclude that there
is no need for imposing a limitation on the amount of color additive to
be used, beyond the limitation that reactants may be used in amounts
not to exceed the minimum reasonably required to accomplish the
intended technical effect. Therefore, we
[[Page 19415]]
are amending the regulations in part 73 (21 CFR part 73) as set forth
in this document. In addition, based upon the factors listed in Sec.
71.20(b) (21 CFR 71.20(b)), we have determined that batch certification
of these color additives is not necessary for the protection of the
public health.
IV. Public Availability of Documents
In accordance with Sec. 71.15 (21 CFR 71.15), the petition and the
documents that we considered and relied upon in reaching our decision
to approve the petition will be made available for public disclosure
(see FOR FURTHER INFORMATION CONTACT). As provided in Sec. 71.15, we
will delete from the documents any materials that are not available for
public disclosure.
V. Environmental Impact
We previously considered the environmental effect of this rule, as
stated in the June 28, 2011, Federal Register notice of petitions for
CAP 1C0291 and CAP 1C0292 (76 FR 37690). We stated that we had
determined, under 21 CFR 25.32(l), that this action ``is of a type that
does not individually or cumulatively have a significant effect on the
human environment'' such that neither an environmental assessment nor
an environmental impact statement is required. We have not received any
new information or comments that would affect our previous
determination.
VI. Paperwork Reduction Act of 1995
This final rule contains no collection of information. Therefore,
clearance by the Office of Management and Budget under the Paperwork
Reduction Act of 1995 is not required.
VII. Objections
This rule is effective as shown in the DATES section; except as to
any provisions that may be stayed by the filing of proper objections.
Any person who will be adversely affected by this regulation may file
with the Division of Dockets Management (see ADDRESSES) either
electronic or written objections regarding this document. Each
objection shall be separately numbered, and each numbered objection
shall specify with particularity the provisions of the regulation to
which objection is made and the grounds for the objection. Each
numbered objection on which a hearing is requested shall specifically
so state. Failure to request a hearing for any particular objection
shall constitute a waiver of the right to a hearing on that objection.
Each numbered objection for which a hearing is requested shall include
a detailed description and analysis of the specific factual information
intended to be presented in support of the objection in the event that
a hearing is held. Failure to include such a description and analysis
for any particular objection shall constitute a waiver of the right to
a hearing on the objection. It is only necessary to send one set of
documents. Identify documents with the appropriate docket number found
in brackets in the heading of this document. Any objections received in
response to the regulation may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday. FDA will
publish notice of the objections that we have received or lack thereof
in the Federal Register.
VIII. References
The following references have been placed on display in the
Division of Dockets Management (see ADDRESSES) and may be seen by
interested persons between 9 a.m. and 4 p.m., Monday through Friday,
and are available electronically at https://www.regulations.gov.
1. Bar[oacute]n, M., K.-H. Hellwich, M. Hess, K. Horie, et al,
``Glossary of Class Names of Polymers Based on Chemical Structure
and Molecular Architecture (IUPAC Recommendations 2009)'', Pure and
Applied Chemistry, 81(6), pp. 1131-1186, 2009.
2. Memorandum from H. Lee, Division of Petition Review,
Chemistry Review Team, to J. Kidwell, Division of Petition Review,
Regulatory Group I, FDA, July 26, 2011.
3. Memorandum from S. Park, Division of Petition Review,
Toxicology Review Team, to M.Harry, Division of Petition Review,
Regulatory Group I, FDA, November 30, 2011.
4. Memorandum from H. Lee, Division of Petition Review,
Chemistry Review Team, to T.Croce, Division of Petition Review,
Regulatory Group II, FDA, August 16, 2011.
5. Memorandum from T.Walker, Division of Petition Review,
Toxicology Review Team, to T.Croce, Division of Petition Review,
FDA, January 13, 2012.
List of Subjects in 21 CFR Part 73
Color additives, Cosmetics, Drugs, Medical devices.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, and
redelegated to the Director, Center for Food Safety and Applied
Nutrition, 21 CFR part 73 is amended as follows:
PART 73--LISTING OF COLOR ADDITIVES EXEMPT FROM CERTIFICATION
0
1. The authority citation for part 73 continues to read as follows:
Authority: 21 U.S.C. 321, 341, 342, 343, 348, 351, 352, 355,
361, 362, 371, 379e.
0
2. Amend Sec. 73.3100 by revising the section heading and paragraph
(a) to read as follows:
Sec. 73.3100 1,4-Bis[(2-hydroxyethyl)amino]-9,10-anthracenedione
bis(2-methyl-2-propenoic)ester copolymers.
(a) Identity. The color additives are the copolymers formed as the
reaction product of 1,4-bis[(2-hydroxyethyl)amino]-9,10-anthracenedione
bis(2-methyl-2-propenoic)ester (C.I. Reactive Blue 247) (CAS Reg. No.
109561-07-1) with one or more vinyl and/or acrylic monomers to form the
contact lens material.
* * * * *
0
3. Amend Sec. 73.3106 by revising paragraph (a) to read as follows:
Sec. 73.3106 1,4-Bis[4-(2-methacryloxyethyl)
phenylamino]anthraquinone copolymers.
(a) Identity. The color additives are the copolymers formed as the
reaction product of 1,4-bis[4- (2-
methacryloxyethyl)phenylamino]anthraquinone (C.I. Reactive Blue 246)
(CAS Reg. No. 121888-69-5) with one or more vinyl and/or acrylic
monomers to form the contact lens material.
* * * * *
Dated: March 25, 2013.
Susan M. Bernard,
Director, Office of Regulations, Policy and Social Sciences, Center for
Food Safety and Applied Nutrition.
[FR Doc. 2013-07294 Filed 3-29-13; 8:45 am]
BILLING CODE 4160-01-P